Next Article in Journal
A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia
Next Article in Special Issue
Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study
Previous Article in Journal
Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets
Previous Article in Special Issue
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(4), 726; doi:10.3390/ijms18040726

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern

1
Dr. Senckenberg Institute of Neurooncology, Goethe University, 60528 Frankfurt, Germany
2
Institute of Neuroradiology, Goethe University, 60528 Frankfurt, Germany
3
Luxembourg Centre of Neuropathology (LCNP), 3555 Dudelange, Luxembourg
4
Laboratoire National de Santé, 3555 Dudelange, Luxembourg
5
Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg
6
NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health (L.I.H.), 1526 Luxembourg, Luxembourg
7
Institute of Neurology (Edinger Institut), Goethe University, 60528 Frankfurt, Germany
*
Author to whom correspondence should be addressed.
Received: 26 February 2017 / Revised: 21 March 2017 / Accepted: 24 March 2017 / Published: 29 March 2017
View Full-Text   |   Download PDF [17157 KB, uploaded 30 March 2017]   |  

Abstract

Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with gliomas showing a gliomatosis cerebri growth pattern is contentious. Due to the marked diffuse and infiltrative growth with less angiogenic tumor growth, it may appear questionable whether bevacizumab can have a therapeutic effect in those patients. However, the development of nodular, necrotic, and/or contrast-enhancing lesions in patients with a gliomatosis cerebri growth pattern is not uncommon and may indicate focal neo-angiogenesis. Therefore, control of growth of these lesions as well as control of edema and reduction of steroid use may be regarded as rationales for the use of bevacizumab in these patients. In this retrospective patient series, we report on 17 patients with primary brain tumors displaying a gliomatosis cerebri growth pattern (including seven glioblastomas, two anaplastic astrocytomas, one anaplastic oligodendroglioma, and seven diffuse astrocytomas). Patients have been treated with bevacizumab alone or in combination with lomustine or irinotecan. Seventeen matched patients treated with bevacizumab for gliomas with a classical growth pattern served as a control cohort. Response rate, progression-free survival, and overall survival were similar in both groups. Based on these results, anti-angiogenic therapy with bevacizumab should also be considered in patients suffering from gliomas with a mainly infiltrative phenotype. View Full-Text
Keywords: primary brain tumors; glioma; glioblastoma; gliomatosis cerebri growth pattern; anti-angiogenic therapy; bevacizumab primary brain tumors; glioma; glioblastoma; gliomatosis cerebri growth pattern; anti-angiogenic therapy; bevacizumab
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Burger, M.C.; Mildenberger, I.C.; Wagner, M.; Mittelbronn, M.; Steinbach, J.P.; Bähr, O. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. Int. J. Mol. Sci. 2017, 18, 726.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top